Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FQGX2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency valued at $16,584.13 for STELARA 90 mg/ml syringes. The delivery order, issued on November 12, 2025, utilizes firm fixed-price pricing with an ultimate completion date of December 4, 2025. This award carries no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) with the Defense Logistics Agency—specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative—which was established on November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036.
The PPV-G GEN V represents a major component of the Department of Defense's $30.3 billion pharmaceutical supply chain modernization strategy, positioning DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply a comprehensive range of pharmaceutical products to military healthcare facilities worldwide. This delivery order for STELARA, an immunosuppressant biologic agent, exemplifies the company's role in fulfilling specialized pharmaceutical requirements critical to DoD medical operations. DMS Pharmaceutical Group's selection as a prime vendor contractor reflects its established performance and capacity to deliver diverse pharmaceutical products, from routine medications to specialty biologics, across the global military medical system.
Quick answers
Who was awarded contract SPE2DR26FQGX2?
SPE2DR26FQGX2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DR26FQGX2 worth?
The government has obligated $16,584 on SPE2DR26FQGX2.
Is contract SPE2DR26FQGX2 an order under another contract?
Yes. SPE2DR26FQGX2 is a delivery order under SPE2DR25D9156, an indefinite delivery contract.
Was contract SPE2DR26FQGX2 competed?
The extent of competition for SPE2DR26FQGX2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award